{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:00:48Z","timestamp":1778943648098,"version":"3.51.4"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","scandinavianjournalpain.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_j.sjpain.2016.10.002_s_001\">\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Cancer pain treatment has improved over the last decades. The majority of this population can be treated effectively with analgesics following the Guidelines of the original World Health Organisation (WHO). Unfortunately 10\u201315% of these patients still suffer from severe and refractory cancer pain, especially in the terminal phases of disease and require additional pain management modalities. Therefore, end-stage clinical interventions are particularly needed to minimize the perception of pain. With intrathecal therapy (ITT), drugs are delivered close to their site of action in the central nervous system avoiding first-pass metabolism and blood\u2013brain barrier. It may improve analgesia with a smaller dose and possibly achieve a reduction in systemic or cerebral side effects compared to oral supplied medication alone. Multimodal analgesia enables further dose reduction with improved analgesia and fewer side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2016.10.002_s_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective research we investigated the effectiveness and side-effect profile of intrathecal morphine, bupivacaine and clonidine. Patients were followed until death occurred. Pain scores and side effects were recorded before initiating ITT (T0), just after initiating ITT (T1), at hospital discharge (T2), in the ambulant setting (T3) and the last obtained scores before death occurred (T4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2016.10.002_s_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine patients were included who suffered from severe and refractory cancer pain, not reacting to conventional pain management or had intolerable side effects. Primary tumour location was pancreatic (4), urothelial (3) and prostate (2). Primary pain was considered neuropathic or mixed neuropathic-nociceptive. The treatment team consisted of an anaesthetist, specialized nurse in coordination with primary physician, treating oncologist and specialized home care.<\/jats:p>\n                    <jats:p>All patients were free of pain after initiation of the intrathecal therapy. The average follow-up period was 11 weeks in which there was a slight increase in NRS-score. In the last days before death occurred, half the patients were still free of pain. There were no problems during insertion of the catheter, device malfunction or infection. No severe adverse events defined as hypotension requiring inotropes, respiratory depression or neurological deficits were observed. Three patients experienced mild hypotension which gradually decreased after clonidine dose adjustment. Lower extremity weakness occurred in three patients as well. After bupivacaine dose adjustment the weakness disappeared in two patients and in one patient the lower extremity weakness persisted as a result of conus compression by tumour.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2016.10.002_s_004\">\n                    <jats:title>Conclusion and implications<\/jats:title>\n                    <jats:p>Multimodal IT treatment with morphine, bupivacaine and clonidine is effective and safe for treating refractory cancer pain in the terminal phase of disease.<\/jats:p>\n                    <jats:p>The study offers an important contribution to literature where there is still lack of convincing evidence about the benefits and harms of this type of pain management in patients with otherwise refractory cancer pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.sjpain.2016.10.002","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T22:45:27Z","timestamp":1478040327000},"page":"39-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Multimodal intrathecal analgesia in refractory cancer pain"],"prefix":"10.1515","volume":"14","author":[{"given":"Thierry C.","family":"Mastenbroek","sequence":"first","affiliation":[{"name":"Department of Anaesthesiology, Pain and Palliative Medicine , Radboud University Nijmegen Medical Centre , Geert Grooteplein Zuid 10, 6525 GA , Nijmegen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca J.","family":"Kramp-Hendriks","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Pain Management, Rijnstate Hospital , Wagnerlaan 55, 6815 AD , Arnhem , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Willem","family":"Kallewaard","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Pain Management, Rijnstate Hospital , Wagnerlaan 55, 6815 AD , Arnhem , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M.","family":"Vonk","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Pain Management, Rijnstate Hospital , Wagnerlaan 55, 6815 AD , Arnhem , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,1,1]]},"reference":[{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_001","doi-asserted-by":"crossref","unstructured":"Cleeland C. Research in cancer pain: what we know and what we need to know. Cancer 1991;67(Suppl.):823\u20137.","DOI":"10.1002\/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_002","unstructured":"Ferrel B. The cost of comfort: economics of pain management in oncology. Oncol Econ 2000;1:56\u201361."},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_003","doi-asserted-by":"crossref","unstructured":"van den Breuken-van everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437\u201349.","DOI":"10.1093\/annonc\/mdm056"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_004","doi-asserted-by":"crossref","unstructured":"Sloan PA, Melzack R. Long-term patterns of morphine dosage and pain intensity among cancer patients. Hosp J 1999;14:135\u201347.","DOI":"10.1080\/0742-969X.1999.11882919"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_005","doi-asserted-by":"crossref","unstructured":"Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011\u20134.","DOI":"10.1126\/science.179.4077.1011"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_006","doi-asserted-by":"crossref","unstructured":"Wang JK, Nauss LA, Thosam JE. Pain relief by intrathecally applied morphine in man. Anesthesiology 1979;50:149\u201351.","DOI":"10.1097\/00000542-197902000-00013"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_007","doi-asserted-by":"crossref","unstructured":"Smith T, Staats S, Deer T, Stearns L, Rauck R, Bootz-Marx R, Bucher E, Catala E, Bryce D, Coyne P, Pool G. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug related toxicity, and survival. J Clin Oncol 2002;20:4040\u20139.","DOI":"10.1200\/JCO.2002.02.118"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_008","doi-asserted-by":"crossref","unstructured":"DuPen S, Kharash E, Williams A, Peterson D, Sloan D, Krembs A. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 1992:293\u2013300.","DOI":"10.1016\/0304-3959(92)90234-3"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_009","doi-asserted-by":"crossref","unstructured":"van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999;15:166\u201372.","DOI":"10.1097\/00002508-199909000-00002"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_010","doi-asserted-by":"crossref","unstructured":"Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995;61:391\u20139.","DOI":"10.1016\/0304-3959(94)00209-W"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_011","doi-asserted-by":"crossref","unstructured":"Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MX, Byas-Smith M. Intrathecal ziconotide in the treatment of refractory cancer pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004;29:63\u201370.","DOI":"10.1001\/jama.291.1.63"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_012","doi-asserted-by":"crossref","unstructured":"Ellis DJ, Dissanayake S, McGuire D, Charapata SG, Staats PS, Wallace MS. Continuous intrathecal infusion of ziconitide for treatment of chronic malignant and non-malignant pain over 12 months: a prospective, open label study. Neuromodulation 2008;11:40\u20139.","DOI":"10.1111\/j.1525-1403.2007.00141.x"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_013","doi-asserted-by":"crossref","unstructured":"Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements with terminal cancer pain. Can J Anesth 1996;43:379\u201383.","DOI":"10.1007\/BF03011718"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_014","doi-asserted-by":"crossref","unstructured":"Tumber P, Fitzgibbon D. The control of severe cancer pain by continuous intrathecal infusion and patient controlled intrathecal analgesia with morphine, bupivacaine and clonidine. Pain 1998:217\u201320.","DOI":"10.1016\/S0304-3959(98)00133-X"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_015","doi-asserted-by":"crossref","unstructured":"van Dongen RT, Crul BJ, de Bock M. Long-term intrathecal infusion of morphine and morphine\/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 1993:119\u201323.","DOI":"10.1016\/0304-3959(93)90191-Q"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_016","doi-asserted-by":"crossref","unstructured":"Veizi I, Hayek S, Narouze S, Pope J, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med 2011:1481\u20139.","DOI":"10.1111\/j.1526-4637.2011.01232.x"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_017","doi-asserted-by":"crossref","unstructured":"Smyth C, Ahmadzai N, Wentzell J, Pardoe A, Tse A, Nguyen T, Goddard Y, Nair S, Poulin P, Skidmore B, Ansari M. Intrathecal analgesia for chronic refractory pain: current and future prospects. Drugs 2015;75:1957\u201380.","DOI":"10.1007\/s40265-015-0471-1"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_018","doi-asserted-by":"crossref","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason N, Mason J, Middleton P, Mrukowicz J, O\u00c7 onnell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW, Zaza S, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490\u20134.","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_019","doi-asserted-by":"crossref","unstructured":"Kurita G, Benthien K, Nordly M, Mercadante S, Klepstad P, Sjogren P. The evidence of neuraxial administration of analgesics for cancer-related pain: a systemic review. Acta Anaesthesiol Scand 2015;59:1103\u20135.","DOI":"10.1111\/aas.12485"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_020","doi-asserted-by":"crossref","unstructured":"Myers J, Chan V, Farvis V, Walker-Dilks C. Intraspinal techniques for pain management in cancer patients: a systemic review. Support Care Cancer 2010;18:1370149.","DOI":"10.1007\/s00520-009-0784-2"},{"key":"2025120909550026013_j_j.sjpain.2016.10.002_ref_021","doi-asserted-by":"crossref","unstructured":"Follet KA, Burchiel K, Deer T, DuPen S, Prager J, Turner MS, Coffey RJ. Prevention of intrathecal drug delivery catheter-related complications. Neuromodulation 2003;6:32\u201341.","DOI":"10.1046\/j.1525-1403.2003.03005.x"}],"container-title":["Scandinavian Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/sjpain\/14\/1\/article-p39.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1877886016301148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1877886016301148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2016.10.002\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2016.10.002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:48:17Z","timestamp":1765280897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2016.10.002\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,1]]},"published-print":{"date-parts":[[2017,1,1]]}},"alternative-id":["10.1016\/j.sjpain.2016.10.002"],"URL":"https:\/\/doi.org\/10.1016\/j.sjpain.2016.10.002","relation":{},"ISSN":["1877-8860","1877-8879"],"issn-type":[{"value":"1877-8860","type":"print"},{"value":"1877-8879","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal intrathecal analgesia in refractory cancer pain","name":"articletitle","label":"Article Title"},{"value":"Scandinavian Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.sjpain.2016.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.sjpain.2016.11.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}